Cytonus Therapeutics, Inc. is a early-stage biotechnology company spin out of the University of California, San Diego (UCSD) which has developed a novel Adoptive Cell Transfer (ACTs) platform dubbed Cargocyte™. Our technology utilizes a variety of enucleated cell lines (allogeneic or autologous) including Mesenchymal Stem Cells and immortalized cells that can carry a multiplicity of therapeutic payloads such as chemokines, cytokines, oncolytic viruses, gene-editing technologies, nanoparticles and small molecules. Our lead therapeutic product GM1215 will be engineered for our sentinel program targeting Pancreatic Adenocarcinoma.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):